Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Adma Biologics (ADMA)

Adma Biologics (ADMA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 213,444
  • Shares Outstanding, K 121,275
  • Annual Sales, $ 42,220 K
  • Annual Income, $ -75,750 K
  • 60-Month Beta 1.32
  • Price/Sales 5.37
  • Price/Cash Flow N/A
  • Price/Book 2.09
Trade ADMA with:

Options Overview

Details
  • Implied Volatility 99.78%
  • Historical Volatility 65.70%
  • IV Percentile 16%
  • IV Rank 5.28%
  • IV High 584.48% on 04/22/20
  • IV Low 72.74% on 04/09/21
  • Put/Call Vol Ratio 0.09
  • Today's Volume 370
  • Volume Avg (30-Day) 1,827
  • Put/Call OI Ratio 0.57
  • Today's Open Interest 66,352
  • Open Int (30-Day) 33,410

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/21
See More
  • Average Estimate -0.17
  • Number of Estimates 3
  • High Estimate -0.15
  • Low Estimate -0.20
  • Prior Year -0.26
  • Growth Rate Est. (year over year) +34.62%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.5700 +8.92%
on 03/30/21
2.2100 -22.62%
on 03/16/21
-0.4100 (-19.34%)
since 03/12/21
3-Month
1.5700 +8.92%
on 03/30/21
3.1105 -45.02%
on 02/10/21
-0.3500 (-16.99%)
since 01/13/21
52-Week
1.5700 +8.92%
on 03/30/21
4.2000 -59.29%
on 07/30/20
-1.0200 (-37.36%)
since 04/13/20

Most Recent Stories

More News
ADMA Biologics Announces Poster Presentation Highlighting Pharmacoeconomic Burden of HIV and HBV Infection in Sexual Assault Patients at the 2021 Academy of Managed Care Pharmacy Virtual Annual Meeting

Poster Presentation Highlights the Unmet Patient Need and Medical Cost Burden Associated with Hepatitis B Infection

ADMA : 1.7100 (-3.93%)
Adma Biologics (ADMA) Reports Q4 Loss, Tops Revenue Estimates

Adma Biologics (ADMA) delivered earnings and revenue surprises of -17.65% and 0.40%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

ADMA : 1.7100 (-3.93%)
Adma Biologics: Q4 Earnings Snapshot

RAMSEY, N.J. (AP) _ Adma Biologics Inc. (ADMA) on Thursday reported a loss of $19.4 million in its fourth quarter.

ADMA : 1.7100 (-3.93%)
ADMA Biologics Reports Fourth Quarter and Full Year 2020 Financial Results

Achieved Full Year 2020 Total Revenues of $42.2 Million, a 44% Increase Over Full Year 2019

ADMA : 1.7100 (-3.93%)
ADMA Biologics to Report Fourth Quarter and Full Year 2020 Financial Results on March 25, 2021

ADMA Biologics, Inc. (Nasdaq: ADMA) ("ADMA"), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced...

ADMA : 1.7100 (-3.93%)
Adma Biologics (ADMA) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

Adma Biologics (ADMA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ADMA : 1.7100 (-3.93%)
ADMA Biologics to Participate in the Jefferies Virtual Plasma Summit

ADMA Biologics, Inc. (Nasdaq: ADMA) ("ADMA" or the "Company"), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics,...

ADMA : 1.7100 (-3.93%)
ADMA Biologics Expands Global Regulatory Approval Presence and Announces FDA Approval to Commence Hepatitis B Plasma Collections

ADMA Biologics, Inc. (NASDAQ: ADMA) ("ADMA"), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced...

ADMA : 1.7100 (-3.93%)
Neptune Wellness Solutions Inc. President Michael Cammarata Named Top 25 Biotech CEO

Neptune Wellness Solutions Inc. President Michael Cammarata Named Top 25 Biotech CEO

ADMA : 1.7100 (-3.93%)
ARNA : 66.40 (+2.53%)
BDSI : 3.45 (-1.43%)
CRIS : 11.37 (+5.08%)
RGLS : 1.1900 (-14.39%)
NEPT : 1.3000 (-1.52%)
NEPT.TO : 1.63 (-0.61%)
ADMA Biologics Presents Late-Breaking Poster Presentation Highlighting Clinical Utility of S. Pneumoniae Hyperimmune Globulin at the 2021 American Academy of Allergy, Asthma & Immunology Virtual Annual Meeting

Poster Presentation Highlights the Need for a Polyclonal Hyperimmune Globulin Targeting S. Pneumoniae to Bridge Vaccination and Seroconversion Across Multiple Serotypes

ADMA : 1.7100 (-3.93%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

ADMA Biologics, Inc. is a specialty immune globulin company. It develops, manufactures and intends to market plasma-based biologics for the treatment and prevention of certain infectious diseases. The Company's target patient populations include immune-compromised individuals who suffer from an underlying...

See More

Key Turning Points

3rd Resistance Point 1.8700
2nd Resistance Point 1.8300
1st Resistance Point 1.7700
Last Price 1.7100
1st Support Level 1.6700
2nd Support Level 1.6300
3rd Support Level 1.5700

See More

52-Week High 4.2000
Fibonacci 61.8% 3.1953
Fibonacci 50% 2.8850
Fibonacci 38.2% 2.5747
Last Price 1.7100
52-Week Low 1.5700

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar